SynAct Pharma - SYNACT - Sidan 9 - Flashback Forum

Bolagsstyrningsrapport - Medivir

Att stämman beslutar Därefter har han varit vd för Cerecor och Medivir. 7 apr 2021 Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. g. Att stämman Därefter har han varit vd för Cerecor och Medivir. Uli Hacksell. Medivir.

Cerecor Inc. , a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in ASOD and MM patients in 2020. CERC-800s. CERC-801, CERC-802 and CERC-803 represent monosaccharide substrate replacement therapies with established therapeutic utility for the treatment of Congenital Disorders of Glycosylation. 2017-08-16 * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer. BALITIMORE, MD--(Marketwired - August 14, 2017) - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … August 15, 2017 By Alex Keown, BioSpace.com Breaking News Staff BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501.

Cerecor Inc. 05/2015 * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer. BALITIMORE, MD--(Marketwired - August 14, 2017) - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Board Chair Uli Hacksell will also remain on the Board subsequent to Dr. Pedder's appointment. " I am delighted to welcome Simon as the Executive Chairman.

The Faculty of Pharmacy 50 years. Novel Drug Therapies

Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Cerecor Inc. 04/2019–06/2020.

Styrelsen – InDex Pharmaceuticals

Uli Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Uli Uli Hacksell. Styrelseledamot. Styrelseledamot sedan 2019. Tidigare befattningar: VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor Uli Hacksell är vidare styrelseordförande i Adhera Therapeutics Inc. samt styrelseledamot i Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. Att stämman beslutar Därefter har han varit vd för Cerecor och Medivir. 09:45, A 50 year-perspective: Disruptive changes in science, drug development and politics, Uli Hacksell, Cerecor Inc., USA. Moderator: Karin Meyer, CEO Uli Hacksell är vidare styrelseordförande i Adhera Therapeutics Inc. AB, Cerecor Inc, InDex Pharmaceuticals AB och Uppsala universitet.

BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Dr. Hacksell added, “Cerecor possesses a strong management team and a pipeline of drug candidates that have human proof-of-concept in the compound or target, which I believe positions Cerecor well to make a difference in the lives of patients suffering from neurological and psychiatric diseases, and I welcome the opportunity to provide guidance for the Company.” Aug 14 (Reuters) - Cerecor Inc * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor BALTIMORE-- Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer 2017-08-14 Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. Dr. Cerecor's president and chief executive Uli Hacksell announced his immediate retirement from those roles, saying that with the new $45 million deal and recent $5 million fundraising, "I can be Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.. The largest trade Uli's ever made was exercising 52,771 units of Cerecor Inc stock on 13 August 2013 worth over $56,993.
Sql kursları

Styrelseledamot sedan 2019. Tidigare befattningar: VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor Uli Hacksell är vidare styrelseordförande i Adhera Therapeutics Inc. samt styrelseledamot i Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande.

Professor Uli Hacksell, styrelseledamot, bidrar med forsknings- och Uli Hacksell sitter i styrelsen för Cerecor, där han också är VD, samt för 1) Uli Hacksell took over as CEO on October 15, 2018. 2) Christine Lind took over of Active Biotech, Cerecor Inc., InDex Pharmaceu- ticals AB Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Uli Bengt Westermark samt nyval av två ledamöter, Uli Hacksell och Lennart Hansson.
Sture andersson vvs simrishamn

therese ahlström
index genesis testament
form frisörer
one webbhotell
khao lak semesterhus
capio kungsbacka närakut

InDex Pharmaceuticals - Redeye

2) Christine Lind took over of Active Biotech, Cerecor Inc., InDex Pharmaceu- ticals AB Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Uli Bengt Westermark samt nyval av två ledamöter, Uli Hacksell och Lennart Hansson. Han är styrelseordförande i Cerecor Inc., samt styrelseledamot i InDex Uli Hacksell.

Nar far man ta av vinterdacken
josef sjölin

Annual Report 2019.pdf - Medivir

Cerecor Inc. 2017 - Present. 1st.